ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 280
- Registration Number
- NCT02267512
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 34
- Registration Number
- NCT02211846
- Locations
- 🇷🇸
Site RS38010 Mother and Child Health Care, Belgrade, Serbia
🇧🇪Site BE32009 Univ.Ziekenhuis Antwerpen, Edegem, Belgium
🇵🇱Site PL48001 Pomnik-Centrum Zdrowia Dziecka, Warsaw, Poland
An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 124
- Registration Number
- NCT02192697
- Locations
- 🇯🇵
Site: 8, Miyagi, Japan
🇯🇵Site: 3, Osaka, Japan
🇯🇵Site: 2, Shizuoka, Japan
Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT02181660
- Locations
- 🇯🇵
Site JP00001, Gunma, Japan
🇯🇵Site JP00004, Tokyo, Japan
🇯🇵Site JP00005, Tokyo, Japan
A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 100
- Registration Number
- NCT02180789
A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 210
- Registration Number
- NCT02179658
A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 262
- Registration Number
- NCT02175784
Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 73
- Registration Number
- NCT02161237
Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 289
- Registration Number
- NCT02160054
- Locations
- 🇯🇵
Site JP00015, Chiba, Japan
🇯🇵Site JP00017, Gifu, Japan
🇯🇵Site JP00003, Ehime, Japan
A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 179
- Registration Number
- NCT02159651
© Copyright 2024. All Rights Reserved by MedPath